Royalty Pharma (RPRX) Stock Statistics & Valuation Metrics

Royalty Pharma has a market cap or net worth of $21.29B. The enterprise value is $30.79B.

Royalty Pharma has 432,293,060 shares outstanding. The number of shares has decreased by -2.65% in one year.

Royalty Pharma’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 4.64%.

The current PE Ratio of Royalty Pharma is 15.9. Royalty Pharma’s PEG ratio is ―.

In the last 12 months, Royalty Pharma had revenue of 2.26B and earned 859.00M in profits. Earnings per share was 1.92.

In the last 12 months, operating cash flow was 2.47B and capital expenditures 0.00, giving a free cash flow of 2.47B billion.

Royalty Pharma pays an annual dividend of $0.22, resulting in a dividend yield of 2.39%

Royalty Pharma upcoming earnings date is Nov 5, 2025, Before Open (Confirmed).

Royalty Pharma as a current ratio of 1.44, with Debt / Equity ratio of 126.34%

In the past 12 months, Royalty Pharma has paid 472.00M in taxes.

Royalty Pharma EV to EBITDA ratio is 14.01, with an EV/FCF ratio of 6.54.

Royalty Pharma has $645.11M in cash and marketable securities with $8.02B in debt, giving a net cash position of $7.38B billion.

Gross margin is 74.83%, with operating margin of 57.07%, and net profit margin of 37.94%.

The average price target for Royalty Pharma is $43.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy